FDA approves Bayer's Ambelvist, a low-dose macrocyclic gadolinium MRI contrast agent

The FDA approved Bayer's Ambelvist (gadopiclenol), a high-relaxivity macrocyclic gadolinium-based contrast agent that delivers diagnostic efficacy at half the standard gadolinium dose. It is indicated for MRI of the CNS and body in patients aged 2 years and older, potentially lo…

• Ambelvist is a macrocyclic GBCA with high relaxivity, allowing a 0.05 mmol/kg dose (half the standard 0.1 mmol/kg).
• Approval was supported by Phase III data demonstrating non-inferior diagnostic visualization versus full-dose gadobutrol (exact figure not reported in source).
• This is the first FDA approval for a high-relaxivity GBCA at a half-dose regimen, expanding the portfolio of macrocyclic agents.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.